Skip to main content

Leen Ann M.'s Form 4 filing

Kalaris Therapeutics, Inc. (KLRS) · filed Nov 16, 2021

Accession no.
0000899243-21-044889
Filed
Nov 16, 2021
Trade date
Nov 12-16, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market sales total $465.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Leen Ann M.CIK 0001763026Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 12, 2021Common StockSSaleDisposed−14,266$22.26F2−$317,561.162,294,876Indirect
Nov 12, 2021Common StockSSaleDisposed−500$23.18F4−$11,5902,294,376Indirect
Nov 15, 2021Common StockSSaleDisposed−6,122$21.92F5−$134,194.242,288,254Indirect
Nov 16, 2021Common StockSSaleDisposed−100$21.76−$2,1762,288,154Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.81 to $22.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.99 to $23.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.75 to $22.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)